Inhibikase Therapeutics, Inc.

IKT · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$11,930-$9,916-$13,679-$12,133
Dep. & Amort.$24$24$13$7
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$4,209$2,042$7,908
Change in WC-$2,148$467$1,328-$1,128
Other Non-Cash$3,462-$358$6,192$0
Operating Cash Flow-$10,593-$5,574-$4,104-$5,346
Investing Activities
PP&E Inv.$0$0-$452$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$38,996$0$0-$50,111
Inv. Sales/Matur.$10,250$9,844$21,506$11,349
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$28,746$9,844$21,054-$38,762
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$251$0$0$99,684
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$385$32$0$0
Financing Cash Flow-$134$32$0$99,684
Forex Effect$0$0$0$0
Net Chg. in Cash-$39,473$4,301$16,951$55,577
Supplemental Information
Beg. Cash$77,743$73,441$56,491$913
End Cash$38,270$77,743$73,441$56,491
Free Cash Flow-$10,593-$5,574-$4,104-$5,346